Irene E M Bultink
Overview
Explore the profile of Irene E M Bultink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nielsen W, Kharouf F, Grajales C, Thayaparan A, Anderson M, Strand V, et al.
Semin Arthritis Rheum
. 2025 Mar;
72:152684.
PMID: 40056477
Objective: To identify candidate Systemic Lupus Erythematosus (SLE) domains from the literature for consideration towards the development of the SLE Core Outcome Set. Methods: This was a comprehensive scoping literature...
2.
3.
Nielsen W, Strand V, Simon L, Pinsker E, Bonilla D, Morand E, et al.
Semin Arthritis Rheum
. 2024 Aug;
68:152520.
PMID: 39106780
Background: Since the development of the OMERACT Systemic Lupus Erythematosus (SLE) Core Outcome Set (COS) in 1998, many new SLE domains have been identified and measures developed, creating a need...
4.
Loeff F, Parodis I, Walhelm T, Jonsen A, Nikolopoulos D, Sjowall C, et al.
J Immunol Methods
. 2024 Jul;
532:113717.
PMID: 38960066
Monitoring belimumab concentrations in patients can be a valuable tool for assessing treatment response and for personalizing drug doses. Various assay formats may be used to measure concentrations of therapeutic...
5.
El Hadiyen F, Tsang-A-Sjoe M, Lissenberg-Witte B, Voskuyl A, Bultink I
Lupus Sci Med
. 2024 Jul;
11(2).
PMID: 38955402
Objective: To determine whether intercurrent infections are a risk factor for subsequent disease flares in systemic lupus erythematosus (SLE). Methods: Demographic and clinical characteristics of 203 patients with SLE participating...
6.
Mucke J, Pencheva D, Parra Sanchez A, Cramer K, Schneider M, Bultink I
Clin Exp Rheumatol
. 2024 May;
42(9):1744-1749.
PMID: 38757283
Objectives: Treat-to-target (T2T) is being recognised as a promising concept to significantly improve the outcomes of patients with systemic lupus erythematosus (SLE). Despite its success being closely tied to patients'...
7.
Blomjous B, de Boer M, van Weissenbruch M, Laan K, Rispens T, Voskuyl A, et al.
Lupus Sci Med
. 2024 Mar;
11(1).
PMID: 38499356
No abstract available.
8.
Abheiden C, Blomjous B, Slaager C, Landman A, Ket J, Salmon J, et al.
Am J Obstet Gynecol
. 2024 Mar;
231(4):408-416.e21.
PMID: 38492714
Objective: Preterm birth is one of the most frequent complications of pregnancy in women with systemic lupus erythematosus. The high indicated preterm birth proportion due to hypertensive disorders of pregnancy...
9.
Kroese S, Abheiden C, Blomjous B, van Laar J, Derksen R, Bultink I, et al.
J Immunol Res
. 2022 May;
2022:9828675.
PMID: 35518569
[This corrects the article DOI: 10.1155/2017/8245879.].
10.
Tsang-A-Sjoe M, Bultink I
Rheumatology (Oxford)
. 2021 Dec;
60(Suppl 6):vi21-vi28.
PMID: 34951924
In this review, the results of recent and ongoing clinical trials in patients with SLE are discussed. After many unsuccessful trials in the past decade, belimumab was the first biologic...